TW200407316A - Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide - Google Patents
Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amideInfo
- Publication number
- TW200407316A TW200407316A TW092121503A TW92121503A TW200407316A TW 200407316 A TW200407316 A TW 200407316A TW 092121503 A TW092121503 A TW 092121503A TW 92121503 A TW92121503 A TW 92121503A TW 200407316 A TW200407316 A TW 200407316A
- Authority
- TW
- Taiwan
- Prior art keywords
- fluorobenzyl
- quinoxaline
- carbamoyl
- dihydroxy
- octyl
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 2
- YEQJVHQCUDMXFG-UHFFFAOYSA-N n-[5-carbamoyl-1-(3-fluorophenyl)-3,8-dihydroxy-8-methylnonan-2-yl]quinoxaline-2-carboxamide Chemical compound C=1N=C2C=CC=CC2=NC=1C(=O)NC(C(O)CC(CCC(C)(O)C)C(N)=O)CC1=CC=CC(F)=C1 YEQJVHQCUDMXFG-UHFFFAOYSA-N 0.000 title abstract 2
- 102000004500 CCR1 Receptors Human genes 0.000 abstract 1
- 108010017319 CCR1 Receptors Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40321602P | 2002-08-12 | 2002-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200407316A true TW200407316A (en) | 2004-05-16 |
Family
ID=31715961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092121503A TW200407316A (en) | 2002-08-12 | 2003-08-06 | Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040072834A1 (zh) |
| EP (1) | EP1539715A1 (zh) |
| JP (1) | JP2005538130A (zh) |
| AP (1) | AP2005003226A0 (zh) |
| AR (1) | AR040839A1 (zh) |
| AU (1) | AU2003250450A1 (zh) |
| BR (1) | BR0313378A (zh) |
| CA (1) | CA2494776A1 (zh) |
| EC (1) | ECSP055588A (zh) |
| GT (1) | GT200300169A (zh) |
| IL (1) | IL166548A0 (zh) |
| IS (1) | IS7674A (zh) |
| MX (1) | MXPA05001781A (zh) |
| NO (1) | NO20050540L (zh) |
| OA (1) | OA12894A (zh) |
| PA (1) | PA8580401A1 (zh) |
| PE (1) | PE20040866A1 (zh) |
| TN (1) | TNSN05035A1 (zh) |
| TW (1) | TW200407316A (zh) |
| UY (1) | UY27928A1 (zh) |
| WO (1) | WO2004014875A1 (zh) |
| ZA (1) | ZA200500768B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY33110A (es) | 2009-12-23 | 2011-07-29 | Ironwood Pharmaceuticals Inc | Moduladores de CRTH2 |
| WO2012009134A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| CN102276539B (zh) * | 2011-06-29 | 2013-08-14 | 赵雪梅 | 一种具有抑菌作用的化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (zh) * | 1962-12-19 | |||
| US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) * | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US6403587B1 (en) * | 1997-02-26 | 2002-06-11 | Pfizer Inc. | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor |
| UA57824C2 (uk) * | 1998-02-05 | 2003-07-15 | Пфайзер Продактс Інк. | Похідні дигідроксигексанової кислоти, фармацевтична композиція, що їх містить (варіанти), та спосіб лікування (варіанти) |
-
2003
- 2003-07-31 OA OA1200500028A patent/OA12894A/en unknown
- 2003-07-31 AU AU2003250450A patent/AU2003250450A1/en not_active Abandoned
- 2003-07-31 WO PCT/IB2003/003464 patent/WO2004014875A1/en not_active Application Discontinuation
- 2003-07-31 CA CA002494776A patent/CA2494776A1/en not_active Abandoned
- 2003-07-31 JP JP2004527195A patent/JP2005538130A/ja active Pending
- 2003-07-31 BR BR0313378-8A patent/BR0313378A/pt not_active Application Discontinuation
- 2003-07-31 AP AP2005003226A patent/AP2005003226A0/xx unknown
- 2003-07-31 MX MXPA05001781A patent/MXPA05001781A/es not_active Application Discontinuation
- 2003-07-31 EP EP03784383A patent/EP1539715A1/en not_active Withdrawn
- 2003-08-05 UY UY27928A patent/UY27928A1/es not_active Application Discontinuation
- 2003-08-06 TW TW092121503A patent/TW200407316A/zh unknown
- 2003-08-06 GT GT200300169A patent/GT200300169A/es unknown
- 2003-08-08 AR AR20030102881A patent/AR040839A1/es unknown
- 2003-08-08 PE PE2003000794A patent/PE20040866A1/es not_active Application Discontinuation
- 2003-08-08 US US10/637,475 patent/US20040072834A1/en not_active Abandoned
- 2003-08-12 PA PA20038580401A patent/PA8580401A1/es unknown
-
2005
- 2005-01-26 ZA ZA200500768A patent/ZA200500768B/xx unknown
- 2005-01-27 IL IL16654805A patent/IL166548A0/xx unknown
- 2005-01-27 IS IS7674A patent/IS7674A/is unknown
- 2005-01-31 NO NO20050540A patent/NO20050540L/no unknown
- 2005-02-03 EC EC2005005588A patent/ECSP055588A/es unknown
- 2005-02-11 TN TNP2005000035A patent/TNSN05035A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200500768B (en) | 2006-07-26 |
| IL166548A0 (en) | 2006-01-15 |
| MXPA05001781A (es) | 2005-04-25 |
| JP2005538130A (ja) | 2005-12-15 |
| TNSN05035A1 (fr) | 2007-05-14 |
| OA12894A (en) | 2006-10-13 |
| EP1539715A1 (en) | 2005-06-15 |
| CA2494776A1 (en) | 2004-02-19 |
| US20040072834A1 (en) | 2004-04-15 |
| GT200300169A (es) | 2004-05-12 |
| IS7674A (is) | 2005-01-27 |
| PA8580401A1 (es) | 2004-02-16 |
| UY27928A1 (es) | 2004-03-31 |
| BR0313378A (pt) | 2005-07-12 |
| AU2003250450A1 (en) | 2004-02-25 |
| AP2005003226A0 (en) | 2005-03-31 |
| AR040839A1 (es) | 2005-04-20 |
| WO2004014875A1 (en) | 2004-02-19 |
| PE20040866A1 (es) | 2004-11-26 |
| ECSP055588A (es) | 2005-04-18 |
| NO20050540L (no) | 2005-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003272285A1 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
| WO2004084835A3 (en) | Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor | |
| WO2005103041A3 (en) | Treatment of cns disorders using cns target modulators | |
| WO2005099756A3 (en) | ErbB ANTAGONISTS FOR PAIN THERAPY | |
| WO2004009590A8 (de) | 4-aminosubstituierte pyrimidinderivate | |
| WO2003084539A3 (en) | New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | |
| WO2004041258A8 (fr) | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie | |
| WO2001066534A3 (en) | Cyclic and bicyclic diamino histamine-3 receptor antagonists | |
| MXPA02012681A (es) | Compuestos de sales de ditosilato de quinazolina. | |
| MXPA05002442A (es) | Imidazolopiridinas y metodos para la elaboracion y uso de las mismas. | |
| TW200621765A (en) | Substituted phenylaminothiazoles and their use | |
| MX2007006754A (es) | Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos. | |
| GB0111186D0 (en) | Novel compounds | |
| WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
| WO2003015713A3 (en) | Treatment of glial tumors with glutamate antagonists | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| MXPA05009014A (es) | Antagonistas del receptor ccr-3. | |
| WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
| TW200407316A (en) | Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide | |
| AU2003215190A8 (en) | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. | |
| WO2005094798A3 (en) | Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists | |
| WO2003092669A3 (en) | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac | |
| WO2005021026A3 (en) | Methods for treating or ameliorating ghrelin-associated diseases and disorders | |
| WO2002069944A3 (de) | Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten | |
| WO2005047278A3 (de) | Substituierte dihydrochinazoline ii |